There are currently 37 active clinical trials seeking participants for Neuroblastoma research studies. The states with the highest number of trials for Neuroblastoma participants are California, Texas, New York and Florida.
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT01109394
Recruiting
Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: - To collect and st... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
07/31/2025
Locations: Children's National Medical Center, Washington, District of Columbia +4 locations
Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Register for Updates
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/31/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +158 locations
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
Register for Updates
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
NCT02605421
Recruiting
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the sta... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/23/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Neuroblastoma
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: University of Alabama, Children's Alabama, Birmingham, Alabama +28 locations
Conditions: Neuroblastoma
Register for Updates
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103
Recruiting
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
07/18/2025
Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +56 locations
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Register for Updates
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
NCT06057948
Recruiting
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Gender:
ALL
Ages:
All
Trial Updated:
07/18/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey +6 locations
Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Register for Updates
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
NCT00107289
Recruiting
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
07/17/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Pheochromocytoma
Register for Updates
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCT01005654
Recruiting
Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to improve detection and treatment options for patients who develop these kinds of cancer. * Researchers are interested in studying the molecular changes that are involved in endocrine cancer development an... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Register for Updates
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06625190
Recruiting
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be highly chemotherapy sensitive, many remain resistant and require multimodalities of treatment. Immun... Read More
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
07/14/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma
Register for Updates
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
NCT07027748
Recruiting
This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study drugs involved in this study are: * Naxitamab (A type of monoclonal antibody) * Irinotecan (A standard of care chemotherapy) * Temozolomide (A standard of care chemotherapy) * Sargramostim (A standard o... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/11/2025
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
NCT04936529
Recruiting
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
Register for Updates
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
NCT06528496
Recruiting
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Gender:
ALL
Ages:
Between 18 months and 19 years
Trial Updated:
06/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
Register for Updates